Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prestwick's Xenazine Faces Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Huntington's disease treatment tetrabenazine received an FDA "approvable" letter March 24.

You may also be interested in...



Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel

FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.

Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel

FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.

FDA Panel To Review Prestwick's Xenazine For Huntington's Chorea

FDA’s Peripheral and Central Nervous Systems Advisory Committee assesses the risk-benefit profile of tetrabenazine for the indication Dec. 7.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel